Vimab Group AB (publ) (STO:VIMAB)

Sweden · Delayed Price · Currency is SEK

3.220

+0.060 (1.90%)

At close: May 26, 2026

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Research Services	318.19M	325.29M	342.35M	227.29M	205.68M
Research Services Growth	-2.18%	-4.98%	50.62%	10.51%	-5.15%
Total	318.19M	325.29M	342.35M	227.29M	205.68M
Total Growth	-2.18%	-4.98%	50.62%	10.51%	-5.15%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Sweden	318.19M	325.29M	342.35M	227.29M	205.68M
Sweden Growth	-2.18%	-4.98%	50.62%	10.51%	-5.15%
Total	318.19M	325.29M	342.35M	227.29M	205.68M
Total Growth	-2.18%	-4.98%	50.62%	10.51%	-5.15%

Source: S&P Global Market Intelligence.